Roche acquired privately held Good Therapeutics and its immuno-oncology platforms for $250 million, plus future milestone payments, on Wednesday.
Tag Archive for: vixarelimab
Genentech has signed an exclusive worldwide license agreement with Chinese pharmaceutical firm Jemincare to allow the latter to develop and commercialize JMKX002992, an androgen receptor degrader being developed for prostate cancer.
